Group 1 - The core viewpoint of the articles highlights the fundraising activities of companies listed on the STAR Market, with a total of 7 companies raising 7.901 billion yuan this year, averaging 1.129 billion yuan per company [1][2] - The company with the highest fundraising amount is Yitang Co., Ltd., which raised 2.497 billion yuan primarily for technology development and reserve funds [1] - Other notable companies include Yingshi Innovation, which raised 1.938 billion yuan for its R&D center and production base, and Xingfu Electronics, which raised 1.168 billion yuan [1] Group 2 - The average initial offering price for STAR Market stocks this year is 21.73 yuan, with Yingshi Innovation having the highest price at 47.27 yuan [1] - The issuance price of Yitang Co., Ltd. is the lowest at 8.45 yuan, while other companies like Sikan Technology and Hanbang Technology have initial prices of 33.46 yuan and 22.77 yuan respectively [1] - The issuance price-earnings ratio for the listed companies ranges from 6.14 to 51.55, with an average of 30.03 and a median of 26.35 [2] Group 3 - Geographically, the majority of the issued STAR Market companies are concentrated in Beijing, Jiangsu, and Hubei, with fundraising amounts led by Beijing at 3.359 billion yuan [2] - The companies with issuance price-earnings ratios above the industry average include Yitang Co., Ltd. and two others, while five companies fall below the industry average [2] - The detailed fundraising data for the listed companies includes their codes, names, issuance dates, prices, price-earnings ratios, and total funds raised [2]

Group 1 - The first meeting of the Supervisory Board of Jiangsu Hanbang Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present [1] - The Supervisory Board approved the proposal to use raised funds to replace self-raised funds that were previously invested in projects and paid issuance expenses, totaling 56.548 million yuan [1] - The use of raised funds for this purpose will not affect the normal implementation of the fundraising projects and complies with relevant regulations [1][2] Group 2 - The voting result for the proposal was 3 votes in favor, 0 votes against, and 0 abstentions [2]

Core Viewpoint - The report provides a verification of Jiangsu Hanbang Technology Co., Ltd.'s pre-investment of self-raised funds into fundraising projects and payment of issuance expenses, confirming compliance with regulatory requirements [1][4]. Group 1: Verification Report - The verification report is intended solely for Jiangsu Hanbang Technology Co., Ltd. to replace self-raised funds with raised funds for specific projects and expenses [2]. - The management of Hanbang Technology is responsible for providing accurate and complete information in accordance with regulatory guidelines [2]. - The registered accountant's responsibility is to independently verify the information provided by the management [3]. Group 2: Fundraising Overview - Hanbang Technology raised a total of RMB 500.94 million by issuing 22 million shares at RMB 22.77 per share, with net funds amounting to RMB 430.67 million after deducting various fees [5][6]. - The company adjusted the investment amounts for its fundraising projects due to the actual funds raised being lower than initially planned [6]. Group 3: Pre-Investment of Self-Raised Funds - As of May 13, 2025, Hanbang Technology invested RMB 46.43 million of self-raised funds into its fundraising projects, which represents 6.74% of the total investment [7][9]. - The specific projects funded include the construction of a chromatography equipment research center and the production of laboratory chromatography purification instruments [7].

一、以自筹资金预先投入募投项目及支付发行费用的鉴证报告…第 1—2 页 二、以自筹资金预先投入募投项目及支付发行费用的专项说明…第 3—5 页 | 三、附件 | ……………………………………………………………第 | 6—10 | 页 | | --- | --- | --- | --- | | | （一）本所营业执照复印件 ………………………………………第 | 6 | 页 | | | （二）本所执业证书复印件 ………………………………………第 | 7 | 页 | | | （三）本所从事证券服务业务备案完备证明材料 ………………第 | 8 | 页 | | | （四）注册会计师执业资格证书复印件 ……………………第 | 9—10 | 页 | 目 录 关于江苏汉邦科技股份有限公司 以自筹资金预先投入募投项目及支付发行费用的 鉴证报告 天健审〔2025〕14555 号 江苏汉邦科技股份有限公司全体股东： 我们鉴证了后附的江苏汉邦科技股份有限公司（以下简称汉邦科技公司）管 理层编制的《以自筹资金预先投入募投项目及支付发行费用的专项说明》。 一、对报告使用者和使用目的的限定 二、管理层的责任 汉邦科技公司管理层的责任是提供 ...

中信证券股份有限公司 关于江苏汉邦科技股份有限公司 使用募集资金置换预先投入募集资金投资项目 及已支付发行费用的自筹资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为江苏 汉邦科技股份有限公司（以下简称"汉邦科技"或"公司"）首次公开发行股票 和持续督导工作的保荐机构，根据《中华人民共和国公司法》《中华人民共和国 证券法》《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 等相关规定，对公司本次拟使用募集资金置换预先投入募集资金投资项目及已支 付发行费用的自筹资金事项进行了审慎核查，具体情况如下： 一、募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意江苏汉邦科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2025〕396 号），公司获准首次向 社会公众公开发行人民币普通股（A 股）股票（以下简称"本次发行"）2,200.00 万股，发行价格为人民币 22.77 元/股，募集资金总额为人民币 50,094.00 万元， 扣除各项发行费用后募集资金净额为人民币 43,067.35 万元，以上募集资金已经 天健会计师事务所（特殊普通合伙）于 2025 ...

证券代码：688755 证券简称：汉邦科技 公告编号：2025-009 江苏汉邦科技股份有限公司 关于使用募集资金置换预先投入募集资金投资项目 及已支付发行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏汉邦科技股份有限公司（以下简称"公司"）于2025年6月17日召开第 一届董事会第二十次会议和第一届监事会第十二次会议，审议通过了《关于使用 募集资金置换预先投入募集资金投资项目及已支付发行费用的自筹资金的议 案》，同意使用募集资金人民币5,654.80万元置换预先投入募集资金投资项目及 已支付发行费用的自筹资金。前述事项符合募集资金到账后六个月内进行置换的 规定。公司监事会发表了明确同意的意见，天健会计师事务所（特殊普通合伙） 出具了鉴证报告，中信证券股份有限公司对本事项出具了明确的核查意见。现将 相关事项公告如下： | 序 | | 募投项目名称 | 投资总额 | 调整前拟投入 募集资金金额 | 调整后拟投入 募集资金金额 | | --- | --- | --- | --- | --- | -- ...

证券代码：688755 证券简称：汉邦科技 公告编号：2025-008 江苏汉邦科技股份有限公司 二、监事会会议审议情况 （一）审议通过了《关于使用募集资金置换预先投入募集资金投资项目及 已支付发行费用的自筹资金的议案》 公司监事会认为，公司本次使用募集资金置换预先投入募投项目及已支付发 行费用的自筹资金总额为 5,654.80 万元。本次使用募集资金置换预先投入募投 项目及已支付发行费用的自筹资金时间距募集资金到账时间不超过 6 个月，不会 影响公司募投项目的正常实施，不存在改变或变相改变募集资金投向和损害公司 及股东利益的情形；符合《上市公司募集资金监管规则》（证监会公告[2025]10 号）《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关法律法规的规定。 关于该事项的具体内容，详见公司同日刊登于上海证券交易所网站 （http://www.sse.com.cn）及公司指定信息披露媒体的《江苏汉邦科技股份有 限公司关于使用募集资金置换预先投入募集资金投资项目及已支付发行费用的 自筹资金的公告》（公告编号：2025-009）。 第一届监事会第十二次 ...

证券代码：688755 证券简称：汉邦科技 公告编号：2025-007 江苏汉邦科技股份有限公司 第一届董事会第二十次会议决议公告 一、董事会会议召开情况 江苏汉邦科技股份有限公司（以下简称"汉邦科技"或"公司"）第一届董 事会第二十次会议于 2025 年 6 月 17 日以现场和通讯相结合的方式在公司会议室 召开，会议通知于 2025 年 6 月 12 日通过通讯方式送达全体董事。本次会议由董 事长张大兵先生召集并主持，会议应出席董事 9 人，实际出席董事 9 人，公司监 事和高级管理人员列席了会议。本次会议的召集、召开和表决程序符合《中华人 民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 关于该事项的具体内容，详见公司同日刊登于上海证券交易所网站 （http://www.sse.com.cn）及公司指定信息披露媒体的《江苏汉邦科技股份有 限公司关于使用募集资金置换预先投入募集资金投资项目及已支付发行费用的 自筹资金的公告》（公告编号：2025-009）。 天健会计师事务所（特殊普通合伙）出具了专项的鉴证报告；保荐机构中信 证券股份有限公司对关于使用募集资金置换预先投入募集资 ...

张维差点错过了这个带来35倍超额收益的项目。 6月11日，影石创新科技股份有限公司（688755.SH，下称" 影石创新 "）在科创板上市，以收盘 价计算，市值超过700亿。该公司创始人、人人网时代的极客网红刘靖康也因此跻身中国最有钱 的"90后"行列。 2019年，基石资本参与了对影石创新的投资。在2019年的基石资本投决会上，至少有四个理由反对 投资影石创新：一是有人认为这个行业的细分市场太小，生命周期存疑；二是竞争格局被认为不乐 观，巨头们在磨刀霍霍；三是公司估值被认为太高了；四是觉得公司"两头在外"，在中美竞争的大 背景下存在风险。 作为基石资本的董事长，张维的意见是： "争议最大的就是生命周期，担心它是一个玩具，但从玩具 走向全消费级就是大疆。而且它也不完全是一个简单的数码产品。公司的估值并不离谱，它还是通过 规模和利润证明了自己。团队也证明了他的能力和特点。我觉得还是尽可能地争取额度，投资1个亿 以上。" 这段话被记录在当年影石创新项目的投委会表决记录中。为了防止有成功后现编造的嫌疑，张维还翻 出了当时的表决记录。 张维从20世纪90年代开始从事投资事业，他投资过的行业像是中国产业经济的"年轮"： ...

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]